Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Xience'

Xience published presentations and documents on DocSlides.

Everolimus-eluting Bioresorbable Vascular Scaffolds in Pati
Everolimus-eluting Bioresorbable Vascular Scaffolds in Pati
by debby-jeon
The ABSORB III trial. Dean J. Kereiakes, MD, . St...
A Randomized
A Randomized
by tatyana-admore
Comparison of . Everolimus-­. Eluting . Absorb B...
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb
by conchita-marotz
Everolimus. Eluting . Bioresorbable. Vascular S...
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb
by briana-ranney
Everolimus. Eluting . Bioresorbable. Vascular S...
by limelighthyundai
Gregg W. Stone MD. Stephen G. Ellis MD and Dean J....
by haroublo
Saturday. , Sep . 22. , 2018, 12:40 PM – 12:52 P...
A Randomized Comparison of
A Randomized Comparison of
by melanie
Everolimus-­. Eluting . Absorb Bioresorbable Vasc...
ABSORB China
ABSORB China
by mitsue-stanley
: . Two-Year Clinical . Results in Patients with ...
"Impact of Procedural Technique on long term adverse outcom
by conchita-marotz
trials“. Manish Narang. Sr. Medical Advisor-APJ...
ABSORB China : Two-Year Clinical
ABSORB China : Two-Year Clinical
by bitechmu
Results in Patients with Coronary Artery Disease R...
ABSORB II Acute gain for BVS vs. DES: 1.15
ABSORB II Acute gain for BVS vs. DES: 1.15
by anderson
vs. 1.46 mm, . p < 0.0001; . IVUS showed lower ...
jx009crrx008cnx009b M mx009cx009bx009crx008c zx
jx009crrx008cnx009b M mx009cx009bx009crx008c zx
by eve
1.ln‹Œaor RŒšo...